Rift Valley Fever

Disease Course and Progression

The natural history of RVF follows a characteristic pattern with potential for late-onset complications weeks after the initial febrile illness.

Exposure (Day 0):

• Mosquito bite (primarily Aedes or Culex species) during periods of heavy rainfall/flooding

• OR direct contact with blood, tissues, or fluids of infected livestock (slaughter, birthing, veterinary procedures, handling aborted material)

• OR rare: inhalation of aerosols in laboratory settings

Incubation Period (Days 1-6, typically 2-6):

• Virus replicates at the inoculation site and in regional lymph nodes

• Viremia develops, with potential dissemination to liver, spleen, and other organs

• The patient is asymptomatic during this period

Acute Febrile Phase (Days 2-10):

• Abrupt onset of fever, often biphasic (initial fever may resolve for 1-2 days before recurring)

• Severe headache, retro-orbital pain, myalgia, arthralgia

• Facial flushing, conjunctival injection

• Nausea, anorexia

• Duration: typically 4-7 days with gradual improvement

• Most patients (~90%) recover fully during this phase

Severe Disease Branching (Variable Timing):

Hemorrhagic Form (Days 2-4 after fever onset):

• Typically the earliest severe complication

• Jaundice, hepatomegaly, and abdominal pain signal liver involvement

• Progressive bleeding manifestations over 24-72 hours

• DIC develops with laboratory coagulopathy

• Multi-organ failure may follow

• Death usually occurs 3-6 days after hemorrhagic onset

Ocular Form (Weeks 1-3 after fever onset):

• Delayed onset, often after apparent recovery from febrile illness

• Gradual visual symptoms: blurring, decreased acuity, scotomas

• Retinal lesions may progress over days to weeks

• Some lesions resolve; macular lesions often cause permanent damage

Encephalitic Form (Weeks 1-4 after fever onset):

• Most delayed severe complication

• Progressive confusion, behavioral changes, headache

• May progress to stupor, coma, focal deficits, seizures

• Prolonged course: recovery over weeks to months

Convalescence:

• Uncomplicated cases: full recovery within 1-2 weeks

• Severe cases: prolonged convalescence over weeks to months

• Late-onset complications (ocular, encephalitic) may emerge after apparent recovery

Diagnosis

RVF diagnosis requires integration of clinical presentation, epidemiological context (geographic, seasonal, occupational), and laboratory confirmation. Diagnosis is particularly challenging because early symptoms are nonspecific.

Clinical Suspicion: RVF should be suspected in febrile patients with:

• Recent travel to or residence in an RVF-endemic area, especially during heavy rainfall/flooding

• Occupational exposure to livestock (butchers, herders, veterinarians, abattoir workers)

• Concurrent livestock abortion storms or animal deaths in the area

• Hemorrhagic manifestations, hepatitis, or retinitis during a febrile illness

Laboratory Diagnostic Methods:

1. RT-PCR (Reverse Transcription Polymerase Chain Reaction):

   • Preferred method for acute diagnosis (first 1-7 days of illness)
   • Detects viral RNA in serum or whole blood
   • High sensitivity and specificity
   • Results within hours at reference laboratories
   • Essential for outbreak confirmation and surveillance

2. IgM ELISA (Enzyme-Linked Immunosorbent Assay):

   • Detectable from approximately day 4-5 of illness
   • IgM persists for 2-3 months
   • Useful for diagnosis in the subacute phase
   • Cross-reactivity with other phleboviruses is possible but uncommon

3. IgG ELISA:

   • Appears 1-2 weeks after IgM
   • 4-fold rise between acute and convalescent sera is confirmatory
   • Useful for serosurveys and retrospective diagnosis

4. Virus Isolation:

   • Possible from blood during the viremic phase (first 4-7 days)
   • Requires BSL-3 or BSL-4 facilities
   • Not practical for routine diagnosis but important for reference characterization

5. Immunohistochemistry:

   • Can detect RVFV antigen in tissue specimens (liver biopsy, post-mortem)
   • Useful for post-mortem confirmation

Differential Diagnosis: The differential is broad and includes: malaria, dengue, Crimean-Congo hemorrhagic fever, Ebola/Marburg, yellow fever, leptospirosis, typhoid fever, viral hepatitis, and bacterial meningitis.

Laboratory Findings:

• Elevated liver transaminases (often markedly: AST/ALT >1000 U/L in severe cases)

• Thrombocytopenia

• Leukopenia early, then leukocytosis

• Prolonged PT/PTT and decreased fibrinogen in DIC

• Elevated creatinine in cases with renal involvement

Travel Advice

RVF poses a risk primarily to travelers visiting affected areas during outbreaks or those with occupational animal exposure. Risk for typical tourists is generally low.

Endemic and At-Risk Regions:

• East Africa: Kenya, Tanzania, Somalia, Sudan, South Sudan — highest historical burden

• Southern Africa: South Africa, Mozambique, Zimbabwe, Madagascar

• West Africa: Mauritania, Senegal, Gambia, Nigeria

• North Africa: Egypt (major epidemic in 1977-1978 with ~200,000 human cases)

• Arabian Peninsula: Saudi Arabia, Yemen (emerged in 2000)

• Potential expansion: Climate models suggest RVF could spread to currently unaffected regions of Asia and southern Europe

Outbreak Triggers: RVF outbreaks are strongly associated with:

• Heavy, sustained rainfall and flooding (linked to ENSO/El Nino events)

• Formation of large temporary water bodies in semi-arid areas

• Rainy seasons following prolonged droughts

Pre-Travel Recommendations:

1. Check WHO Disease Outbreak News and CDC travel health notices for active RVF outbreaks
2. Consult a travel medicine specialist if visiting rural livestock-rearing areas in endemic countries
3. No human vaccine is available
4. Pack insect repellent, protective clothing, and permethrin
5. If traveling for veterinary or agricultural purposes, bring appropriate PPE (gloves, goggles, masks)

During Travel:

• Apply insect repellent consistently during daytime and evening hours

• Avoid handling livestock, especially during birthing or slaughter

• Do not consume raw milk or undercooked meat in affected areas

• Avoid contact with sick or dead animals

• During active outbreaks, minimize time near flooded areas with abundant mosquitoes

Post-Travel:

• Seek medical attention if fever develops within 2-14 days of returning from an endemic area

• Inform clinicians of travel history and any animal exposure

• Report any visual symptoms developing in the weeks following a febrile illness during travel (delayed ocular manifestation)

Epidemiology

Rift Valley fever is an emerging zoonotic disease with a growing geographic range and significant epidemic potential linked to climate variability.

Geographic Distribution:

• Africa: Documented in over 30 countries across sub-Saharan and North Africa

• Arabian Peninsula: Saudi Arabia and Yemen (first emergence outside Africa in 2000)

• Indian Ocean Islands: Madagascar, Mayotte, Comoros

• Potential range expansion: Mathematical models predict risk of establishment in southern Europe, the Middle East, and parts of Asia where competent vectors and susceptible livestock are present

Major Historical Outbreaks:

• Egypt 1977-1978: An estimated 200,000 human cases and 594 deaths following Aswan Dam construction and irrigation changes

• East Africa 1997-1998: Associated with strong El Nino; 89,000 estimated cases in Kenya and Somalia

• Saudi Arabia/Yemen 2000: First outbreak outside Africa; 886 cases, 124 deaths

• Kenya/Tanzania/Somalia 2006-2007: 1,062 cases, 394 deaths (WHO); devastating livestock losses

• South Africa 2010-2011: 302 cases, 25 deaths

• Niger/Mauritania 2016: 64 human cases

• Kenya/Somalia 2018: Resurgent activity with cases reported during El Nino conditions

Transmission Ecology:

• Mosquito-borne: Primary transmission via Aedes (transovarially infected) and secondary amplification by Culex, Anopheles, and other genera

• Transovarial transmission: RVFV is maintained in Aedes mosquito eggs during inter-epidemic periods (dry years). Eggs survive in soil for years and hatch when flooded.

• Zoonotic: Livestock (sheep, cattle, goats, camels) serve as amplifying hosts with high viremia

• Direct contact: Significant route for occupational infections; aerosol exposure in laboratory settings

Burden Estimation: True burden is difficult to quantify due to:

• Mild cases are indistinguishable from other febrile illnesses (malaria, dengue)

• Limited surveillance infrastructure in most endemic countries

• Outbreaks occur in remote pastoral areas with poor healthcare access

• Estimated tens of thousands of cases during major epidemics; inter-epidemic cases are underdetected

Seasonality and Climate Linkage:

• Outbreaks are strongly seasonal, linked to rainfall and flooding patterns

• Inter-epidemic periods can last 5-20 years in any given location

• ENSO prediction models can forecast outbreaks 2-4 months in advance with reasonable accuracy

Prognosis and Outcomes

The prognosis for RVF varies substantially depending on the clinical form.

Mild/Uncomplicated RVF:

• Excellent prognosis with full recovery expected

• Self-limiting illness resolving in 4-7 days

• Overall CFR <1% for all RVF infections combined

• Residual fatigue and myalgia may persist for 1-2 weeks

• Convalescent immunity appears to be long-lasting

Ocular Disease:

• Onset 1-3 weeks post-acute illness

• 1-10% of affected patients develop permanent vision loss

• Up to 50% with macular involvement have significant permanent visual impairment

• Peripheral retinal lesions generally have better visual outcomes

• Risk of late complications (retinal detachment, neovascularization) persists for months

Meningoencephalitis:

• CFR approximately 5-10%

• Onset typically 1-4 weeks after acute illness

• Recovery is slow (weeks to months)

• Residual neurological deficits in a significant proportion of survivors: cognitive impairment, motor deficits, personality changes

• Some patients may require long-term rehabilitation

Hemorrhagic Fever:

• Most severe form with CFR of approximately 50%

• Death typically occurs 3-6 days after onset of hemorrhagic symptoms

• Severe hepatic necrosis is the primary cause of death

• DIC and multi-organ failure contribute to mortality

• Survivors may develop chronic liver disease

Predictors of Severe Disease:

• High viral load in early illness

• Elevated liver transaminases (AST, ALT) early in course

• Thrombocytopenia and coagulopathy

• Immunosuppression

• Direct animal tissue exposure (may indicate higher inoculum)

Long-Term Outcomes:

• Most patients (>90%) who survive the acute phase make a full recovery

• Combined severe manifestations (e.g., hemorrhagic + encephalitic) carry the worst prognosis

• Post-infectious fatigue syndrome is reported but poorly characterized

• Immunity following natural infection appears durable